Use of prostate-specific antigen (PSA) isoforms for the detection of prostate cancer in men with a PSA level of 2-10 ng/ml: Systematic review and meta-analysis - Editorial comment

European Urology

Volumn 48, Issue 3, 2005, Pages 398-399

  Stenman, Ulf Hakan ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ANTICHYMOTRYPSIN; PROSTATE SPECIFIC ANTIGEN;

CANCER DIAGNOSIS; COMPLEX FORMATION; DIAGNOSTIC ACCURACY; DISEASE SEVERITY; FOLLOW UP; HUMAN; NOTE; OBSERVER VARIATION; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER;

EID: 23944484453     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (10)

1. Stenman UH, Leinonen J, Alfthan H, Rannikko S, Tuhkanen K, Alfthan O. A complex between prostate-specific antigen and alpha-1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res 1991;51:222-6.
2. Roddam A, Duffy M, Hamdy F, Milford Ward A, Patnick J, Price C, et al. Use of PSA isoforms for the detection of prostate cancer in men with a PSA level of 2-10 ng/ml: systematic review and meta-analysis. Eur Urol 2005 this issue.
3. 1- antichymotrypsin. Clin Chem 1993;39:2098-103.
4. 1-antichymotrypsin complex together with free or total PSA. Clin Chem 2003;49:97-103.
5. Draisma G, Boer R, Otto SJ, Van der Cruijsen IW, Damhuis RA, Schröder FH, et al. Lead times and overdetection due to prostatespecific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 2003;95:868-78.
6. D'Amico AV, Chen MH, Roehl KA, Catalona WJ. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. New Engl J Med 2004;351:125-35.
7. Sakr WA, Grignon DJ, Crissman JD, Heilbrun LK, Cassin BJ, Pontes JJ, et al. High grade prostatic intraepithelial neoplasia (HGPIN) and prostatic adenocarcinoma between the ages of 20-69: an autopsy study of 249 cases. In Vivo 1994;8:439-43.
8. Hugosson J, Aus G, Lilja H, Lodding P, Pihl CG. Results of a randomized, population-based study of biennial screening using serum prostate-specific antigen measurement to detect prostate carcinoma. Cancer 2004;100:1397-405.
9. Southwick PC, Catalona WJ, Partin AW, Slawin KM, Brawer MK, Flanigan RC, et al. Prediction of post-radical prostatectomy pathological outcome for stage T1c prostate cancer with percent free prostate specific antigen: a prospective multicenter clinical trial. J Urol 1999;162:1346-51.
10. Finne P, Auvinen A, Aro J, Juusela H, Määttänen L, Rannikko S, et al. Estimation of prostate cancer risk on the basis of total and free prostate-specific antigen, prostate volume and digital rectal examination. Eur Urol 2002;41:619-27.